Letter from the Editor | JITC Editor Picks | JITC Meet-the-Editor Session at ASCO| Popular Archive Articles
Letter from the Editor
Hello JITC Readers,
Welcome to the latest JITC Digest. As we move into May, it also means the journal now enters its 12th year of publication, one set to be full of exciting and promising changes. Beginning next month, JITC’s Incoming Editor-in-Chief Dr. Michael Lotze will be “Incoming” no more. Moving forward, he will be welcoming you to these monthly Digests to share recent journal highlights and JITC news. While I will continue to serve in a supporting role as Interim Editor-in-Chief over the coming months, I look forward to seeing his vision for the journal and its readership unfold as we complete this harmonious transition of leadership.
On that note, I would also like to call attention to a special opportunity for those you of attending the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Lotze will be hosting a JITC Meet-the-Editor Session at the SITC booth (#12040), 12–1 pm CT on Sunday, June 2nd. Please come say hello and discuss your research with Dr. Lotze!
While we eagerly await the research to be unveiled at ASCO, there are numerous highlights in this month’s JITC Digest. Through in vitro and in vivo results, Nicholas P. Casey and colleagues demonstrate cancer antigen 125 (CA125) as a target for treating MUC16-positive malignancies in ovarian cancer, opening the path for developing other chimeric antigen receptor molecules. Findings in murine models of prostate cancer from Anusha Muralidhar et al show greater anti-tumor response and overall survival by delivering androgen deprivation therapy (ADT) prior to a novel targeted radionuclide therapy (TRT), 90Y-NM600, than when TRT preceded ADT treatment, revealing a sequencing preference for ADT and TRT and suggesting a potential approach for treating advanced human prostate cancer. Be sure to check out these highlights and more below!
Thank you for the opportunity to share this marvelous journal with you over the years. It has been an immense honor.
Regards,
James L. Gulley, MD, PhD, FACP
Interim Editor-in-Chief
Journal for ImmunoTherapy of Cancer
JITC Editor Picks
|
Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival
|
|
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha
Journal for ImmunoTherapy of Cancer 2024;12:e008880 (9 April 2024)
RESEARCH
Summary:
Oncolytic herpesviruses such as oncolytic herpes simplex virus (oHSV) replicate selectively in cancer cells and trigger anti-tumor immune responses. oHSVs that express granulocyte macrophage-colony stimulating factor (GM-CSF) have been approved for the treatment of melanoma, but not other cancers like glioblastoma (GBM). GBM is an immunosuppressive and often fatal primary brain tumor. This study examined how oHSVs could be used to target GBMs. The investigators developed an oHSV that expresses IL-2 (G47Δ-mIL2), an immunotherapy that stimulates T cell growth, which resulted in a cancer targeted T cell stimulation. Using orthotopic mouse GBM models, they found that treatment with G47Δ-mIL2 in HSV permissive models increased CD8+ T cell infiltration in a CD4+ T cell-dependent manner, and significantly prolonged median survival. Additionally, no toxicity that is typically associated with systemic IL-2 treatment was observed. These data show a promising oHSV for the treatment of GBMs.
|
|
|
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
|
|
Nicholas P Casey, Katrin Kleinmanns, Christopher Forcados, Pascal F Gelebart, Sandy Joaquina, Martine Lode, Emmanuelle Benard, Fatemeh Kaveh, Benjamin Caulier, Christiane Helgestad Gjerde, Elvira García de Jalón, David J Warren, Kristina Lindemann, Erik Rokkones, Ben Davidson, Marit Renee Myhre, Gunnar Kvalheim, Line Bjørge, Emmet McCormack, Else Marit Inderberg, Sébastien Wälchli
Journal for ImmunoTherapy of Cancer 2024;12:e008179 (11 April 2024)
RESEARCH
Summary:
Ovarian cancer (OC) is the eighth most common cancer in women globally, for both incidence and death. New immunotherapy strategies are needed for treatment of OC, and development of chimeric antigen receptor (CAR) T cell therapy on different OC antigens is ongoing. This study examined the suitability of the cancer antigen 125 (CA125) extracellular domain of the MUC16 transmembrane protein as a CAR T cell target. CA125 also currently serves as a serum biomarker for OC because it is often cleaved off of MUC16. CAR T cells targeting the CA125 portion of the extracellular domain were generated, and one candidate, K101CAR, was identified as being potent and specific both in vitro and in vivo in patient-derived tumor models. Additionally, serum CA125 did not counteract the effects of K101CAR T cell. These data show that CA125 is a good target for treating MUC16-positive malignancies, and opens the possibility to develop additional CAR T molecules for the treatment of OC. |
|
|
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
|
|
Florian Hornsteiner, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Christoph H Tripp, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Natascha Hermann-Kleiter, Athanasios Seretis, Sudhir Morla, David Mullins, Francesca Finotello, Zlatko Trajanoski, Guido Wollmann, Franca Ronchese, Marc Schmitz, Ian F Hermans, Patrizia Stoitzner
Journal for ImmunoTherapy of Cancer 2024;12:e008606 (17 April 2024)
RESEARCH
Summary:
The use of tumor-targeted therapy in melanoma effectively drives tumor regression but is not sustained long-term due to the emergence of resistance. This study examined the myeloid landscape during tumor-targeted therapy in a preclinical melanoma mouse model that contains the murine homolog to the BRAFV600E mutation. BRAF-inhibitor tumor-targeted therapy led to a T cell-inflamed tumor microenvironment (TME), and both the TME and the tumor-draining lymph nodes (LN) expressed subpopulations of type 2 classical dendritic cells (cDC2). cDC2s were shown to be important in the TME and tumor-draining LN T cell responses as demonstrated by only a partial loss of response in cDC1 deficiency. Further, total loss of DC and inflammatory monocytes resulted in a regulatory T cell accumulation and loss of tumor immune response. These data provide insight into the importance of activated DCs in the immune responses in the TME and tumor-draining LN during tumor-targeted therapy, which may facilitate future combined therapy strategies.
|
|
|
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors
|
|
Anusha Muralidhar, Reinier Hernandez, Zachary S Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P Weichert, Douglas G McNeel
Journal for ImmunoTherapy of Cancer 2024;12:e008372 (24 April 2024)
RESEARCH
Summary:
Recurrent prostate cancer is treated with a combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) for localized disease. However, in metastatic castration-resistant prostate cancer, targeted radionuclide therapy (TRT) is often used instead of EBRT. This study examined the efficacy of the combination and sequence of ADT and a novel TRT, 90Y-NM600, in murine prostate tumor models. Results showed that when ADT was given prior to TRT there was a greater anti-tumor response and overall survival than when TRT preceded ADT treatment. Flow cytometry analysis of the tumors showed that in the ADT → TRT samples there were more CD4+ and CD8+ T cells, whereas the TRT → ADT samples had more myeloid derived suppressor cells (MDSCs). When MDSC presence was abrogated through GR1+ MDSC depletion or CXCL2 antagonism, anti-tumor responses improved. These data suggest a sequential approach to explore in clinical trials in advanced human prostate cancer.
|
Other Recent JITC Articles
Meet-the-Editor Session at ASCO
|
|
For those attending the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, visit the SITC booth #12040 in the exhibit hall and meet JITC Incoming Editor-in-Chief Dr. Michael T. Lotze during the JITC Meet-the-Editor Session, 12–1 pm CT on Sunday, June 2nd. Stop by to say hello to Dr. Lotze, share your research, and learn more about JITC.
For additional information during ASCO 2024, check out JITC’s X/Twitter and LinkedIn profiles.
|
Popular Archive Articles
The selections below represent some of the most popular content published in JITC over the past two years. Explore additional thematic content in JITC's Collections or access the rest of JITC's archives for a look at all the journal has to offer.
|
The selections below represent some of the most popular content published in JITC over the past two years. Explore additional thematic content in JITC's Collections or access the rest of JITC's archives for a look at all the journal has to offer.
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
Ryan C. Augustin, Robert D. Leone, Aung Naing, Lawrence Fong, Riyue Bao, Jason J. Luke
Journal for ImmunoTherapy of Cancer 2022;10:e004089 (8 February 2022)
REVIEW
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer
Yijia Xu, Han Zeng, Kaifeng Jin, Zhaopei Liu, Yu Zhu, Le Xu, Zewei Wang, Yuan Chang, Jiejie Xu
Journal for ImmunoTherapy of Cancer 2022;10:e003416 (25 March 2022)
RESEARCH
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu
Journal for ImmunoTherapy of Cancer 2022;10:e005543 (2 December 2022)
RESEARCH
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
Xinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K Jain
Journal for ImmunoTherapy of Cancer 2023;11:e005583 (10 March 2023)
SHORT REPORT
|
|
APC Discounts
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 35% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted through 2024. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
Become a SITC Member Today!
|
|
JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. For additional information regarding these discounts, as well as institutional arrangements and editor/reviewer discounts, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.
|